Advertisement

European Journal of Clinical Pharmacology

, Volume 74, Issue 9, pp 1197–1198 | Cite as

The race for drug approvals: hasten slowly?

  • Alain Braillon
Letter to the Editor

Keywords

FDA EMA SMC Accelerated approval Market withdrawal Harm-benefit Surrogate 

Notes

Compliance with ethical standards

Conflict of interest

AB is an expert for several task forces at the French Drug Agency (Agence nationale de sécurité du médicament et des produits de santé).

References

  1. 1.
    Zeukeng MJ, Seoane-Vazquez E, Bonnabry P. A comparison of new drugs approved by the FDA, the EMA, and Swissmedic: an assessment of the international harmonization of drugs. Eur J Clin Pharmacol 2018. Online Feb 22. doi:  https://doi.org/10.1007/s00228-018-2431-7, 74, 811, 818
  2. 2.
    Svensson S, Menkes DB, Lexchin J (2013) Surrogate outcomes in clinical trials: a cautionary tale. JAMA Intern Med 173:611–612CrossRefPubMedGoogle Scholar
  3. 3.
    Johnson JR, Ning YM, Farrell A, Justice R, Keegan P, Pazdur R (2011) Accelerated approval of oncology products: the food and drug administration experience. J Natl Cancer Inst 103:636–644CrossRefPubMedGoogle Scholar
  4. 4.
    Kim C, Prasad V (2015) Cancer drugs approved on the basis of a surrogate end point and subsequent overall survival: an analysis of 5 years of US Food and Drug Administration approvals. JAMA Intern Med 175:1992–1994CrossRefPubMedGoogle Scholar
  5. 5.
    Onakpoya IJ, Heneghan CJ, Aronson JK (2015) Delays in the post-marketing withdrawal of drugs to which deaths have been attributed: a systematic investigation and analysis. BMC Med 13:26CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Prasad V (2014) The withdrawal of drugs for commercial reasons. The incomplete story of Tositumomab. JAMA Intern Med 174:1887–1888CrossRefPubMedGoogle Scholar
  7. 7.
    Bolland MJ, Grey A (2016) Ten years too long: strontium ranelate, cardiac events, and the European Medicines Agency. BMJ 354:i5109CrossRefPubMedGoogle Scholar
  8. 8.
    Prescrire. Towards better patient care: drugs to avoid in 2018. Prescrire Int 2018;27:107-1–107-9. Available at http://english.prescrire.org/en/AA26644A665789B5BD5C3814F73AE19D/Download.aspx Accessed 16 April 2018

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.University HospitalAmiensFrance

Personalised recommendations